These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Early stopping designs based on progression-free survival at an early time point in the initial cohort. Litwin S; Wong YN; Hudes G Stat Med; 2007 Oct; 26(24):4400-15. PubMed ID: 17345568 [TBL] [Abstract][Full Text] [Related]
26. Further results on a multiple-testing procedure for clinical trials. Seigel D; Milton RC Biometrics; 1983 Dec; 39(4):921-8. PubMed ID: 6671127 [TBL] [Abstract][Full Text] [Related]
27. The process of clinical trials: a model for successful clinical trial participation. Lengacher CA; Gonzalez LL; Giuliano R; Bennett MP; Cox CE; Reintgen DS Oncol Nurs Forum; 2001 Aug; 28(7):1115-20. PubMed ID: 11517845 [TBL] [Abstract][Full Text] [Related]
28. Design options for molecular epidemiology research within cohort studies. Rundle AG; Vineis P; Ahsan H Cancer Epidemiol Biomarkers Prev; 2005 Aug; 14(8):1899-907. PubMed ID: 16103435 [TBL] [Abstract][Full Text] [Related]
30. Case series analysis for censored, perturbed, or curtailed post-event exposures. Farrington CP; Whitaker HJ; Hocine MN Biostatistics; 2009 Jan; 10(1):3-16. PubMed ID: 18499654 [TBL] [Abstract][Full Text] [Related]
31. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials. Tamura RN; Huang X Clin Trials; 2007; 4(4):309-17. PubMed ID: 17848492 [TBL] [Abstract][Full Text] [Related]
32. Comparison of epidemiologic methods for active surveillance of vaccine safety. McClure DL; Glanz JM; Xu S; Hambidge SJ; Mullooly JP; Baggs J Vaccine; 2008 Jun; 26(26):3341-5. PubMed ID: 18462849 [TBL] [Abstract][Full Text] [Related]
33. Aspects of the design and analysis of high-dimensional SNP studies for disease risk estimation. Prentice RL; Qi L Biostatistics; 2006 Jul; 7(3):339-54. PubMed ID: 16443924 [TBL] [Abstract][Full Text] [Related]
34. Informing the selection of futility stopping thresholds: case study from a late-phase clinical trial. Hughes S; Cuffe RL; Lieftucht A; Garrett Nichols W Pharm Stat; 2009; 8(1):25-37. PubMed ID: 18383194 [TBL] [Abstract][Full Text] [Related]
35. Design and analysis of group sequential logrank tests in maximum duration versus information trials. Kim K; Boucher H; Tsiatis AA Biometrics; 1995 Sep; 51(3):988-1000. PubMed ID: 7548714 [TBL] [Abstract][Full Text] [Related]
36. Case-control methods in the presence of multiple failure times and competing risks. Lubin JH Biometrics; 1985 Mar; 41(1):49-54. PubMed ID: 4005386 [TBL] [Abstract][Full Text] [Related]
37. A group-sequential design for clinical trials with treatment selection. Stallard N; Friede T Stat Med; 2008 Dec; 27(29):6209-27. PubMed ID: 18792085 [TBL] [Abstract][Full Text] [Related]
38. Epidemiological study designs. Diomidus M Stud Health Technol Inform; 2002; 65():126-35. PubMed ID: 15460223 [TBL] [Abstract][Full Text] [Related]
39. Maximum likelihood estimation of the attributable fraction from logistic models. Greenland S; Drescher K Biometrics; 1993 Sep; 49(3):865-72. PubMed ID: 8241375 [TBL] [Abstract][Full Text] [Related]